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A tripanossomíase africana, também conhecida como doença do sono, é responsável por 
um grande número de mortes na África. Até o presente, não há tratamento seguro e eficaz 
disponível. A enzima aldolase do parasita Trypanosoma brucei é um alvo atrativo e validado 
para o desenvolvimento de novos fármacos. Uma série de ésteres fosfóricos foi estudada com 
uma combinação de métodos de planejamento de fármacos. Modelos de relações quantitativas 
tridimensionais entre estrutura e atividade (3D QSAR) foram gerados empregando-se a análise 
comparativa de campos moleculares (CoMFA). Resultados significativos foram obtidos 
(r2 = 0,95, coeficiente de correlação de validação não-cruzada, e q2 = 0,80, coeficiente de 
correlação de validação cruzada), indicando a capacidade de predição do melhor modelo para 
novas moléculas. O modelo foi então utilizado para predizer valores das variáveis dependentes 
(pKi) de um conjunto teste de compostos, e os valores obtidos apresentaram boa concordância 
com os resultados experimentais. A integração de estudos de QSAR 3D, docagem molecular e 
dinâmica molecular forneceram informações úteis em relação às bases estruturais para a inibição 
seletiva da enzima alvo.
Human African trypanosomiasis, also known as sleeping sickness, is a major cause of death 
in Africa, and for which there are no safe and effective treatments available. The enzyme aldolase 
from Trypanosoma brucei is an attractive, validated target for drug development. A series of 
alkyl-glycolamido and alkyl-monoglycolate derivatives was studied employing a combination of 
drug design approaches. Three-dimensional quantitative structure-activity relationships (3D QSAR) 
models were generated using the comparative molecular field analysis (CoMFA). Significant results 
were obtained for the best QSAR model (r2 = 0.95, non-cross-validated correlation coefficient, and 
q2 = 0.80, cross-validated correlation coefficient), indicating its predictive ability for untested 
compounds. The model was then used to predict values of the dependent variables (pKi) of an 
external test set, and the predicted values were in good agreement with the experimental results. 
The integration of 3D QSAR, molecular docking and molecular dynamics simulations provided 
further insight into the structural basis for selective inhibition of the target enzyme.
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Introduction
The African continent has been devastated by the 
enormous impact of the neglected tropical diseases (NTDs), 
as they disproportionately affect the poorest and most 
vulnerable populations. For decades, NTDs represent an 
insurmountable obstacle to the socioeconomic development 
of communities in the infested areas. Among the most 
important diseases is human African trypanosomiasis (HAT, 
or sleeping sickness), which is caused by two sub-species 
of protozoa, Trypanosoma brucei gambiense and 
Trypanosoma brucei rhodesiense. HAT threatens 
approximately 60 million people in the sub-Saharan 
Africa, causing long-term disability and death. The disease, 
transmitted by the bite of tsetse flies, is fatal in untreated 
cases.1,2
The limited existing chemotherapy, consisting of old 
drugs such as suramin (discovered in 1920), pentamidine 
(1921), melarsoprol (1949) and eflornithine (1991), suffers 
from a variety of drawbacks including poor efficacy, 
resistance and serious side effects.3 Moreover, due to these 
limitations and growing drug resistance, combination 
therapy has been employed as an important clinical 
alternative.4,5 According to the World Health Organization 
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(WHO), there is an urgent need for new drugs that are safe, 
affordable and effective for use in humans.1
The identification of novel molecular targets is of great 
importance in drug discovery.6 Fructose-1,6-bisphosphate 
aldolase from T. brucei (EC 4.1.2.13) has been considered 
an attractive and validated drug target for HAT therapy.7 
The enzyme, a homotetramer of 164 KDa, belongs to the 
type I class of aldolases, which in contrast to type II, does 
not require a metal ion to catalyze the cleavage of the 
substrate.8,9 Trypanosoma brucei aldolase plays a pivotal 
role in the glycolytic flux, the sole source of ATP (adenosine 
triphosphate) in the parasite, as it cleaves the hexose 
fructose-1,6-bisphosphate into two trioses, glyceraldehyde-
3-phosphate and dihydroxyacetone-phosphate.10,11 Therefore, 
aldolase has been exploited in medicinal chemistry efforts 
toward new lead compounds against HAT.12-14
Chemoinformatic tools have been employed to 
successfully analyze biological and chemical data, 
creating useful information for drug design. Among them, 
quantitative structure-activity relationships (QSAR) have 
been widely used for the design of a variety of biologically 
active compounds.15-17 Comparative molecular field 
analysis (CoMFA), one of the most popular 3D QSAR 
methods, is based on the assumption that the activity of a 
series of compounds is directly related to ligand-receptor 
interactions, requiring the 3D structural alignment of the 
data set molecules in order to calculate the interaction 
molecular fields.18 In the present work, the CoMFA 
approach was employed to investigate a series of aldolase 
inhibitors. Molecular docking and molecular dynamics 
(MD) studies were also used to explore the molecular basis 
underlying the inhibition of T. brucei aldolase, considering 
the stability and evolution of the main intermolecular 
interactions in such a dynamic system.19-22
Methodology
Computational approach 
The QSAR modeling analyses, calculations and 
visualizations for CoMFA were performed using the 
SYBYL 8.0 software suite (Tripos Inc., St. Louis, USA), 
running on CentOS Linux workstations. The 3D structures of 
the molecules were built employing the Powell method and 
the Tripos force field, implemented in SYBYL 8.0.23,24 Each 
conformation was further energetically minimized and 
submitted to charge calculation applying the semi-empirical 
quantum chemistry program MOPAC 6.0. The Austin 
method 1 (AM1) was applied and charges were calculated 
by electrostatic potential (ESP), with a 1.4 scaling factor for 
van der Waals distances and a 0.4 increment between layers 
in ESP.25,26 Molecular docking was performed with GOLD 
5.0 software (Cambridge Crystallographic Data Centre, 
Cambridge, UK). The molecular dynamics simulations were 
carried out with NAMD 2.7 at a Dell PowerEdge 1950 II 
cluster and visualized with VMD 1.9 program (University 
of Illinois, Urbana, USA).
Data set
The data set employed for the QSAR studies was 
selected from the literature and consists of a series of 38 
alkyl-glycolamido and alkyl monoglycolate phosphoric 
esters along with Ki values (the dissociation constant 
for the enzyme-inhibitor complex), determined for the 
aldolase enzyme from rabbit muscle.27-29 Table 1 includes 
the structures and corresponding pKi (dependent variables) 
values for the complete set of inhibitors. The complete 
data set was divided into training (compounds 2, 4, 5, 
7, 8, 10-13, 15, 16, 18-21, 23-30, 32-38) and test sets 
(compounds 1, 3, 6, 9, 14, 17, 22 and 31) in the ratio 
of approximately 80 and 20%, respectively. In order to 
select appropriate training and test sets, a statistical cluster 
analysis was carried out using the software Tsar version 
3.3 (Accelrys, San Diego, USA), employing the complete 
linkage clustering method.30 The structurally diverse 
molecules having a significant coverage of property values 
were included in both sets. Thus, the data set is suitable for 
QSAR model development. The predictive ability of the 
final models was assessed by the full cross-validated (q2), 
partial least squares (PLS), leave-one-out (LOO) and leave-
many-out (LMO) methods.31 Progressive scrambling was 
applied to determine the sensitivity of the QSAR models 
to chance correlations. External model validation was 
performed with the test set (Table 1), whose compounds 
were not considered for QSAR model generation. After 
generation of the PLS training set models, values of the 
dependent variables (pKi) were predicted for the test set 
compounds, allowing the determination of predictive-r2 
(non-cross-validated correlation coefficient) values.
Structural alignment and molecular docking
The structural alignment of the data set molecules was 
carried out using the X-ray coordinates of the T. brucei 
aldolase enzyme (PDB ID 1F2J, resolution of 1.9 Å).8 The 
preparation of the structure and the docking procedure were 
accomplished with the GOLD 5.0 program.32 After removal 
of the water molecules, hydrogen atoms were added in 
standard geometry. The binding site was defined as a sphere 
with a radius of 10 Å around the side chain nitrogen atom of 
Lys239. The cavity detection function was applied to restrict 
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Table 1. Chemical structures and corresponding pKi values of the aldolase inhibitors
Cpd Structure pKi / M Cpd Structure pKi / M
1 2.44 2 2.58
3 2.85 4 3.27
5 3.14 6 3.48
7 3.28 8 3.00
9 3.48 10 4.26
11 3.60 12 3.24
13 1.67 14 2.10
15 2.14 16 1.53
17 1.31 18 1.92
19 2.26 20 2.06
21 1.64 22 1.72
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Cpd Structure pKi / M Cpd Structure pKi / M
23 1.88 24 2.22
25 1.82 26 1.88
27 1.79 28 1.88
29 2.30 30 2.30
31 1.96 32 2.52
33 2.18 34 1.52
35 1.30 36 1.77
37 2.30 38 2.11
Table 1. continuation
the atom selection to solvent accessible surface. It was 
attributed to the residues of Arg52, Arg158, Arg313, Lys116, 
Lys156 and Lys239, a rotational freedom of 10 degrees. 
GoldScore function was employed to evaluate and score 
the binding solutions. Each molecule of the data set was 
docked 20 times and the top scoring conformations were 
further considered for the CoMFA studies. The complete 
aligned data set is depicted in Figure 1.
3D QSAR CoMFA
To engender useful QSAR models and access the 
contributions of electrostatic and steric fields to the affinity 
of the data set inhibitors, CoMFA studies were performed 
upon the 3D molecular alignment illustrated in Figure 1.
The aligned training set molecules were posed in a 3D 
grid box, with a grid spacing of 2.0 Å in x, y and z directions, 
Figure 1. Structural alignment of the inhibitors into the active site of 
T. brucei aldolase.
with an extension of 4.0 Å in each direction beyond the 
molecules. The molecular descriptors (CoMFA steric and 
electrostatic fields) were generated at each grid point 
with Tripos force field and a sp3 carbon atom possessing 
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a +1 net charge, as a probe. CoMFA region focusing was 
applied to refine the models by increasing the weight for 
those lattice points which are most pertinent to the model. 
This proceeding enhances the resolution and predictive 
power of the subsequent PLS analyses. The default value 
of 30 kcal mol-1 was stipulated as the maximum steric and 
electrostatic energy cutoff. The statistical analyses of the 
models were performed with the q2LOO and q2LMO PLS 
methods and the CoMFA standard for variable scaling.
Molecular dynamics
In order to explore key molecular interactions responsible 
for the binding affinity of the inhibitors, molecular dynamics 
simulations were performed with NAMD and CHARMM 
force field for the aldolase enzyme in complex with 
compounds 4 and 10.33,34 The topology and parameters of the 
ligands were obtained using the SwissParam server (Swiss 
Institute of Bioinformatics, Switzerland) and evaluated 
with vacuum equilibrations.35 The charge distribution of 
each ligand was obtained by calculating the Mulliken 
charges employing Mulliken Population Analyses at the 
Hartree-Fock level with a 6-31G* basis set, using the 
PC-GAMESS/Firefly 7.1 software.36-38 Subsequently, the 
complexes obtained by docking the compounds 4 and 10 into 
the aldolase binding site were solvated in a water box with 
approximate dimensions of 80 × 80 × 90 Å, with a layer of 
10 Å from the protein extremities. Afterwards, both systems 
were neutralized adding a minimal number of sodium and 
chloride counter-ions. This procedure provided each system 
with a total of 47,200 atoms. Protein and ligand ionization 
states were set based on a pH of 7.0. Long-range electrostatic 
interactions were calculated through the Particle Mesh Ewald 
method using a cut-off of 12 Å.39-41
For the two complexes, protein and ligand were then 
subjected to a restrained run of 100 ps, whereby only water 
molecules could move in order to avoid possible steric 
conflicts. The entire systems were then relieved, minimized 
during 20 ps and equilibrated in simulations of 10 ns using 
a NTP ensemble, at a temperature of 298 K and pressure 
of 1.0 atm. Pressure and temperature were retained by 
the Nosé-Hoover piston pressure control and Langevin 
Dynamics, respectively.42-44 The entire simulation process 
was repeated 5 times for each protein-ligand complex.
Results and Discussion
Biochemical data
The data set consists of a series of alkyl-glycolamido and 
alkyl-monoglycolate phosphoric esters, which are 
structurally related to fructose-bisphosphate (Table 1). 
The biochemical data (Ki values) were collected under the 
same experimental conditions, a fundamental requisite for 
QSAR studies.18 For modeling purposes, the dependent 
variables were converted into the corresponding pKi 
values (−log Ki), which span approximately three orders 
of magnitude.
This data set was selected because of its suitability for 
QSAR modeling, considering the appropriate structural 
diversity and the quality of the experimental data. In 
addition, it should be noted that no 3D QSAR studies are 
available in the literature for this enzyme, emphasizing the 
importance of the present work.
The selection of training and test sets was executed in 
such a way that structurally diverse molecules having a 
wide range of data were included in both sets. From the 
38 inhibitors, 30 were selected as members of the training 
set, for model development and the other 8 (compounds 
1, 3, 6, 9, 14, 17, 22 and 31) as members of the test set 
for external validation. The predictive ability of the final 
model was assessed by PLS regression with LOO and 
LMO cross-validation and also for pKi prediction for the 
test set.
Enzyme homology and docking strategy
The aldolase enzyme from T. brucei has a 49% of 
sequence identity compared to the rabbit muscle and 
human enzymes (Figure 2), and the three proteins have 
the same tridimensional structural folding patern.8 An 
analysis of the amino acid residues illustrates the high 
conservation between the binding site of the rabbit 
muscle and parasite enzymes (Figure 3). Therefore, it 
could be expected that inhibitors of the rabbit muscle 
enzyme would bind in a similar fashion to the T. brucei 
aldolase. In fact, this is the case for mannitol-bisphosphate 
(MBP), a known inhibitor of the rabbit muscle and 
T. brucei aldolase enzymes, which is structurally related 
to the data set compounds employed in this work.45 The 
binding mode of MBP is illustrated in Figure 4, in which 
the crystallographic conformation of the inhibitor into 
the active site of rabbit muscle aldolase (PDB ID 1ZAJ) 
is compared with the docking solution upon the parasitic 
enzyme.46 As can be seen, the inhibitor binding poses are 
very similar for both enzymes. Therefore, the structure of 
T. brucei aldolase was employed to obtain the structural 
alignment for the CoMFA studies and then, to investigate, 
through docking and molecular dynamics, the key 
intermolecular interactions involved in the binding affinity 
of the inhibitors for the parasitic enzyme.
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CoMFA statistical results
The aligned structures of the inhibitors (Figure 1) were 
submitted to several CoMFA analyses, which initially 
resulted in a model with q2 of 0.72 and r2 of 0.77. These 
results were considered liable to improvement, particularly 
regarding the fit of the data, represented by the r2 value. 
Hence, the region focusing weighted by standard deviation 
coefficient (SDC) was applied, with values ranging 
from 0.3 to 0.9. This strategy not only increased both 
correlation coefficients, leading to improved models, but 
also resulted in the refinement of the 3D contour maps. 
The statistical results are presented in Table 2. As can be 
seen, significant correlation coefficients were obtained for 
CoMFA models 2 and 3. The best model (3) exhibited q2 
of 0.80 and r2 of 0.95.
The stability of the models was further confirmed 
applying the LMO cross validation method, resulting 
in a q2 value of 0.73 for 5 cross validation groups. For 
10 groups, a value of 0.76 for q2 was obtained. These 
values are comparable to those obtained by using LOO 
cross validation.
Although the cross-validated correlation coefficient 
may adequately represent the internal consistency and 
predictive power of the models for untested compounds, the 
external validation process is the most significant validation 
method. Therefore, the predictive ability of model 3 was 
assessed by predicting the affinity of an external test set of 
8 compounds. The values of experimental and predicted pKi 
Figure 2. Amino acid sequence alignment of T. brucei, rabbit muscle and human liver aldolases. Numbers correspond to amino acid positions of the 
T. brucei enzyme. Conserved amino acid residues are highlighted.
Figure 3. Overlapping of the active site amino acid residues of the 
aldolase enzymes from rabbit muscle (in yellow) and T. brucei (in 
grey). The inhibitor mannitol-bisphosphate is shown in ball-and-stick 
representation (in blue).
Figure 4. Crystallographic conformation of MBP (in blue) adopted within 
the rabbit muscle aldolase binding site (in yellow). The MBP inhibitor (in 
magenta) is docked into the T. brucei binding site (in gray).
Table 2. CoMFA results according to the variation of SDC values
Model q2 SEP r2 SEE N F
Fraction
S E
1 0.73 0.37 0.85 0.27 2 81.02 0.45 0.55
2 0.76 0.36 0.95 0.16 4 124.80 0.51 0.49
3 0.80 0.33 0.95 0.16 4 124.82 0.48 0.52
q2: leave-one-out (LOO) cross-validated correlation coefficient; N: optimum number of components; r2: non-cross-validated correlation coefficient; SEP: 
standard error of prediction; SEE: standard error of estimate; F: F-test value; S: steric field; E: electrostatic field. Grid spacing of 2 Å in all cases. Model 1, 
SDC = 0.3; model 2, SDC = 0.6; model 3, SDC = 0.9.
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values for the test set compounds are shown in Table 3, and 
the graphic results are displayed in Figure 5. The good 
correlation between experimental and predicted pKi values 
for the test set compounds indicates the ability of the QSAR 
model to predict the affinity of novel inhibitors within this 
structural diversity (r2pred = 0.84).
CoMFA contour maps
The relationships between structure and activity of 
the data set compounds were further investigated through 
the interpretation of the CoMFA steric and electrostatic 
contour maps for model 3 (Figure 6). The contour maps 
show regions in the 3D space where changes of steric and 
electrostatic properties correlate with respective changes 
in the affinity of the inhibitors for the enzyme.
The CoMFA steric contour, represented by green 
polyhedra, indicates that bulky groups are advantageous 
for activity, while yellow regions advert that bulky groups 
are detrimental for activity. The map revealed that the 
compounds possessing only one phosphate group are 
aligned in such a way that the extremity lacking the other 
group are oriented always to the same side of the active 
site. From Figure 6, it can be assumed that the presence of 
bulky groups in this extremity would be beneficial to the 
inhibitor affinity. An example is compound 23, which does 
not hold a second bulky group (such as phosphate) and 
has a binding affinity 1000-fold lower than compound 10.
Regarding the CoMFA electrostatic contour maps, blue 
regions indicate that electropositive groups are favorable, 
while red polyhedra give support for electronegative 
groups. Figure 6 shows red regions surrounding one of 
the phosphate groups of compound 10 (Figure 6a) and the 
phosphate lacking extremity of compound 23 (Figure 6b). 
This finding is consistent with the experimental data since 
compounds presenting electronegative groups in this 
region have higher affinity for the enzyme. Moreover, the 
red regions surrounding the amide and the ester groups of 
both compounds demonstrate the importance of acceptor 
groups within the hydrocarbon chain, as indicated by the 
experimental data and docking studies.
Enzyme-inhibitor interactions
The understanding of protein-ligand interactions 
is essential for the design and optimization of enzyme 
inhibitors. In the present study, it was explored an approach 
that combines 3D QSAR, molecular docking and molecular 
dynamics to investigate the intermolecular interactions 
Figure 5. Plot of experimental values of pKi vs. the corresponding 
predicted and estimated values for the 30 training (solid circles) and 8 
test (open triangles) set compounds.
Figure 6. CoMFA contour maps (model 3) for inhibitors 10 (a) and 23 (b).
Table 3. External validation: experimental and predicted pKi values for 
the test set compounds
Inhibitor pKi , 
experimental
pKi , 
predicted Residual
a
1 2.44 3.00 −0.56
3 2.85 3.13 −0.28
6 3.48 3.02 0.46
9 3.48 3.30 0.18
14 2.10 1.87 0.23
17 1.31 1.60 −0.29
22 1.72 1.77 −0.05
31 1.96 1.86 0.10
aDifference between experimental and predicted pKi values.  
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between T. brucei aldolase and the data set inhibitors. 
An analysis of the biochemical data for these compounds 
shows that the best inhibitors possess two phosphoric 
esters in their chemical structures (Table 1). Moreover, the 
presence of an amide substituent within the hydrocarbon 
chain increases the affinity of the compounds. In order 
to rationalize these experimental results, identifying key 
motifs associated to the inhibitory activity and asserting 
the importance of polar groups within the hydrocarbon 
chain, it was selected compounds 10 (the highest affinity 
inhibitor of the data set, pKi = 4.26) and 4 (pKi = 3.27) for 
molecular dynamics studies. The chemical structure of 
these compounds differs only for the presence of an amide 
group within the hydrocarbon chain of compound 10. The 
docking conformations of these ligands are depicted in 
Figure 7.
The binding conformations of the two compounds 
revealed that the phosphoric esters are necessary for 
electrostatic interactions with Lys116, Arg158 and 
Arg313. This moiety also establishes ion-dipole contacts 
with residues Ser281, Ala312 and Arg313. Furthermore, 
compound 10 which possess an amide group, establishes 
additional ion-dipole interactions between its carbonyl 
oxygen and residues Lys156 and Lys239, as shown in 
Figure 7b.
The stability of these interactions was further evaluated 
by molecular dynamics. The average root-mean-square 
deviations (RMSD) obtained during the simulations 
from the starting initial conformations of the protein-
ligand complexes and for the apoenzyme are depicted in 
Figure 8a. The plots show very similar RMSD patterns, 
with equilibrium being achieved mutually after 6 ns. The 
analysis of RMSD shown in Figure 8b indicates that both 
ligands are maintained into the binding site of aldolase 
with the same orientation during the entire simulations. A 
slightly lower RMSD profile was observed for compound 
10 in comparison with compound 4. The higher stability of 
compound 10 could be related to its observed higher affinity 
to the aldolase enzyme (10-fold higher than compound 4). 
It was not observed the release of the ligand in any of the 
5 simulations for each system. Furthermore, the plot of 
the root-mean-square fluctuation (RMSF) of all protein 
residues for both systems (Figure 8c) shows that the binding 
site residues exhibit the same mobility in the presence of 
both ligands. As expected, the flexible N-terminal aldolase 
tail (residues 1-20, Figure 8c) presents high mobility during 
all simulations.
To verify the conservation of the interaction pattern 
observed by molecular docking between both ligands and 
the aldolase binding site, and to evaluate the key elements 
responsible for the higher affinity of compound 10, the 
length of the interactions identified by docking between 
these two inhibitors and the binding site were evaluated 
during the MD simulations (Figure 9).
As shown in Figure 9, the intermolecular interactions 
observed in the initial conformation were well maintained 
during the simulations. The general profile of all 
interactions is very similar and linear for both ligand 
complexes. Furthermore, both aldolase inhibitors seem to 
be stabilized mainly by common electrostatic interactions. 
The residue Ser281 establishes two ion-dipole interactions 
with the phosphate group from both ligands (Figure 7; 
Figures 9c and d). Furthermore, the observance of three 
electrostatic interactions involving Arg313 indicates the 
importance of this residue for the biological activity of this 
class of inhibitors (Figures 9f, 9g and 9h). Arginine 313 
maintains two ion-dipole interactions with the oxygen O4 
of the ligands. The first one involves the backbone amino 
group, and the second one the side chain amino group 
(Figures 9f and 9h). Also, the protonated nitrogen of Arg313 
participates in a strong ionic interaction with the oxygen O5 
of the ligands (Figure 9g). Residues Lys116, Arg158 and 
Figure 7. (a) Binding conformation of compound 4 showing electrostatic interactions between the ligand phosphates and the binding site residues of 
aldolase. (b) Binding conformation of compound 10 showing a very similar interaction pattern to that of compound 4, with the presence of additional 
interactions between the amide group of the ligand and the residues Lys156 and Lys239 of the enzyme.
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Ala312 also participate in electrostatic interactions in both 
ligand complexes, increasing the binding stability.
Essentially, the higher affinity of compound 10 is 
basically correlated with its additional steady ion-dipole 
interactions between the oxygen atom O8 of the amide 
group and the residues Lys156 and Lys239 (Figures 9i and 9j). 
This finding reveals the importance of the presence of such 
a polar group in the backbone of this inhibitor.
Structural basis for the design of selective inhibitors
Considering several molecular aspects involved in 
the binding of the data set inhibitors to the T. brucei 
aldolase enzyme, as well as the information provided by 
the CoMFA contour maps, it was investigated some key 
structural aspects which could lead to selectivity towards 
the parasite enzyme. An analysis of the superimposed 
structures of the T. brucei and human liver (PDB ID 
1QO5) aldolases (Figure 10) revealed that the Gly302 and 
Thr38 residues in the human enzyme are replaced by 
Ala312 and Ser48 in the parasite enzyme, respectively.47 
Moreover, it is observed that a neutral phenylalanine 
residue (Phe79), present in the human aldolase is replaced 
by a positively charged histidine residue (His88) in the 
T. brucei enzyme. The data set inhibitors do not occupy 
the binding pocket where the Phe79 and His88 residues are 
located, thus the elongation of the compounds beyond the 
phosphate moiety through the attachment of a negatively 
charged or a polar group to provide a better occupation of 
this pocket would be beneficial to the selectivity towards 
the T. brucei aldolase.
Conclusions
The molecular modeling strategy employed in this 
work was useful to reveal key molecular characteristics 
related to the binding affinity and selectivity of this series 
of alkyl-glycolamido and alkyl-monoglycolate aldolase 
inhibitors. The statistically significant QSAR model was 
able to predict the pKi values for the test set compounds. 
Moreover, the steric and electrostatic contour maps provided 
evidences for the importance of electronegative and bulky 
functional groups in the hydrocarbon scaffold of the data 
set molecules. The docking studies and MD simulations 
revealed important molecular insights for the best inhibitor 
of the series into the binding site of T. brucei aldolase. 
Finally, the examination of the main differences between 
the human and the parasitic enzyme was profitable to gather 
Figure 8. (a) RMSD of aldolase as apoenzyme (yellow line) and in the presence of compounds 4 (blue line) and 10 (orange line) during the MD simulations. 
(b) RMSD of compounds 4 and 10 during the MD simulations. (c) Average fluctuations of each aldolase residue during the simulations for the apoenzyme and 
the complexes with compounds 4 and 10. Each curve is an average of 5 independent simulations.
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knowledge on the structural basis underlying the design 
of new inhibitors with increased affinity and selectivity.
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